Nanotheranostics: A tactic for cancer stem cells prognosis and management

Misra, Ranjita; Kandoi, Sangeetha; Varadaraj, Sudha; Vijayalakshmi, S.; Nanda, Anima; Verma, Rama Shanker

doi:10.1016/j.jddst.2019.101457

Cited by 14 publications

(9 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is an urgent need to solve the problems of current anti-BCSC agents, such as poor solubility, instability, unfavorable biodistribution, and high toxicity induced by off-target effects. 3 , 130 , 137 NDDSs have the potential to address this need. NDDSs can passively target tumor tissues owing to their enhanced permeability and retention (EPR) effects.…”

Section: Nddss Against Bcscsmentioning

confidence: 99%

“…An increasing amount of evidence indicates that tumors are heterogeneous tissues with different types of cells, such as cancer stem cells and non-cancer stem cells. 137 Some therapeutic agents have been reported to eliminate cancer stem cells; however, cancer cells can also spontaneously transition to cancer stem cells; thus, the depletion of cancer stem cells alone is neither sufficient nor effective as a therapeutic measure. 3 , 130 , 185 Instead of targeting only cancer stem cells or non-cancer stem cells, combination strategies designed to simultaneously eradicate both cell types may have the potential to improve therapeutic outcomes.…”

Section: Nddss Against Bcscsmentioning

confidence: 99%

“…For example, NDDSs can overcome many of the undesirable properties of conventional agents against BCSCs. 3 , 130 , 137 Moreover, although normal stem cells and BCSCs may have similar properties, such as self-renewal, 80 NDDSs could reduce, at least to some extent, the toxicity on normal stem cells by selectively accumulating in tumor tissue with the help of the EPR effect to minimize any impact on normal stem cells. 131 In addition, the targeting capacity of NDDSs to BCSCs could be further enhanced by the modification of NDDSs with BCSCs surface marker-specific ligands/antibodies, resulting in a further increase in the anti-BCSC ability of NDDSs while reducing toxicity on normal tissue.…”

Section: Nddss Against Bcscsmentioning

confidence: 99%

See 2 more Smart Citations

Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

Lv¹,

Shi²,

Wu³

et al. 2021

IJN

View full text Add to dashboard Cite

Breast cancer stem cells (BCSCs), also known as breast cancer initiating cells, are reported to be responsible for the initiation, progression, therapeutic resistance, and relapse of breast cancer. Conventional therapeutic agents mainly kill the bulk of breast tumor cells and fail to eliminate BCSCs, even enhancing the fraction of BCSCs in breast tumors sometimes. Therefore, it is essential to develop specific and effective methods of eliminating BCSCs that will enhance the efficacy of killing breast tumor cells and thereby, increase the survival rates and quality of life of breast cancer patients. Despite the availability of an increasing number of anti-BCSC agents, their clinical translations are hindered by many issues, such as instability, low bioavailability, and off-target effects. Nanosized drug delivery systems (NDDSs) have the potential to overcome the drawbacks of anti-BCSC agents by providing site-specific delivery and enhancing of the stability and bioavailability of the delivered agents. In this review, we first briefly introduce the strategies and agents used against BCSCs and then highlight the mechanism of action and therapeutic efficacy of several state-of-the-art NDDSs that can be used to treat breast cancer by eliminating BCSCs.

show abstract

Section: Nddss Against Bcscsmentioning

confidence: 99%

Section: Nddss Against Bcscsmentioning

confidence: 99%

Section: Nddss Against Bcscsmentioning

confidence: 99%

See 1 more Smart Citation

Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

Lv¹,

Shi²,

Wu³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“… 2 Although both diagnosis and treatment go hand in hand, early prognosis gives the treatment of these infections an upper edge, so the development of rapid and sensitive identification methods is paramount for better dissemination of therapeutics in these challenging times. 4 , 5 In the current scenario, the main strategy to control the Covid‐19 pandemic depends on testing and diagnosis of the disease at early stages. Reverse transcription PCR (RT‐PCR) testing remains the primary method for diagnosing SARS‐CoV‐2 although some clinicians may utilise chest computed tomography (CT) scans as a more reliable way to assess the stage of the disease.…”

Section: Introductionmentioning

confidence: 99%

Nanobiosensor‐based diagnostic tools in viral infections: Special emphasis on Covid‐19

Misra

Acharya

Nehru

2021

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

Summary The rapid propagation of novel human coronavirus 2019 and its emergence as a pandemic raising morbidity calls for taking more appropriate measures for rapid improvement of present diagnostic techniques which are time‐consuming, labour‐intensive and non‐portable. In this scenario, biosensors can be considered as a means to outmatch customary techniques and deliver point‐of‐care diagnostics for many diseases in a much better way owing to their speed, cost‐effectiveness, accuracy, sensitivity and selectivity. Besides this, these biosensors have been aptly used to detect a wide spectrum of viruses thus facilitating timely delivery of correct therapy. The present review is an attempt to analyse such different kinds of biosensors that have been implemented for virus detection. Recently, the field of nanotechnology has given a great push to diagnostic techniques by the development of smart and miniaturised nanobiosensors which have enhanced the diagnostic procedure and taken it to a new level. The portability, hardiness and affordability of nanobiosensor make them an apt diagnostic agent for different kinds of viruses including SARS‐CoV‐2. The role of such novel nanobiosensors in the diagnosis of SARS‐CoV‐2 has also been addressed comprehensively in the present review. Along with this, the challenges and future position of developing such ultrasensitive nanobiosensors which should be taken into consideration before declaring these nano‐weapons as the ideal futuristic gold standard of diagnosis has also been accounted for here.

show abstract

“…14 These nanosystems deliver the drugs and siRNA into cancer cells by enhanced permeability and retention (EPR) effect thus enhancing the therapeutic effects of the drug. 15 Polymeric nanoparticles (NPs) have shown more efficiency as a drug delivery platform. For instance, poly(lactic-co-glycolide) (PLGA) has been mostly used for various biomedical use due to its biocompatible and biodegradable nature.…”

Section: Introductionmentioning

confidence: 99%

Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction: Triple-negative breast cancer (TNBC) is a lethal tumor with an advanced degree of metastasis and poor survivability as compared to other subtypes of breast cancer. TNBC which consists of 15 % of all types of breast cancer is categorized by the absence of expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER2). This is the main reason for the failure of current hormonal receptor-based therapies against TNBCs, thus leading to poor patient outcomes. Therefore, there is a necessity to develop novel therapies targeting this devastating disease. Methods: In this study, we have targeted TNBC by simultaneous activation of apoptosis through DNA damage via cytotoxic agent such as paclitaxel (PAC), inhibition of PARP activity via PARP inhibitor, olaparib (OLA) and inhibiting the activity of FOXM1 proto-oncogenic transcription factor by using RNA interference technology (FOXM1-siRNA) in nanoformulations. Experiments conducted in this investigation include cellular uptake, cytotoxicity and apoptosis study using MDA-MB-231 cells. Results: The present study validates that co-delivery of two drugs (PAC and OLA) along with FOXM1-siRNA by cationic NPs, enhances the therapeutic outcome leading to greater cytotoxicity in TNBC cells. Conclusion: The current investigation focuses on designing a multifunctional drug delivery platform for concurrent delivery of either PAC or PARP inhibitor (olaparib) and FOXM1 siRNA in chitosan-coated poly(D, L-lactide-co-glycolide) (PLGA) nanoparticles (NPs) with the ability to emerge as a front runner therapeutic for TNBC therapy.

show abstract

Nanotheranostics: A tactic for cancer stem cells prognosis and management

Cited by 14 publications

References 126 publications

Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

Nanosized Drug Delivery Systems for Breast Cancer Stem Cell Targeting

Nanobiosensor‐based diagnostic tools in viral infections: Special emphasis on Covid‐19

Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy

Contact Info

Product

Resources

About